Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-vaccination sensitization with ICRC vaccine

R S Vallishayee1, M D Gupte, D S Anantharaman

  • 1CJIL Field Unit (ICMR), Madras.

Indian Journal of Leprosy
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lyme Borreliosis, a public health concern in India: Findings of <i>Borrelia burgdorferi</i> serosurvey from two states.

Medical journal, Armed Forces India·2024
Same author

Expanded Indian National Rotavirus Surveillance Network in the Context of Rotavirus Vaccine Introduction.

Indian pediatrics·2016
Same author

Bayesian model, ecological factors & transmission of leprosy in an endemic area of South India.

The Indian journal of medical research·2016
Same author

DHR-ICMR Guidelines for diagnosis & management of Rickettsial diseases in India.

The Indian journal of medical research·2015
Same author

Factors associated with diarrhoea in young children and incidence of symptomatic rotavirus infection in rural West Bengal, India.

Epidemiology and infection·2014
Same author

Evaluation of the Erosive Potential of Various Pediatric Liquid Medicaments: An in-vitro Study.

Journal of international oral health : JIOH·2014

The ICRC vaccine, a candidate anti-leprosy treatment, was found to be safe in a trial involving 368 individuals. It demonstrated a significant sensitizing effect, measured by Rees

Area of Science:

  • Immunology
  • Vaccinology
  • Dermatology

Background:

  • Leprosy remains a significant global health challenge.
  • Development of effective anti-leprosy vaccines is crucial for disease control.
  • The ICRC vaccine is a candidate under investigation.

Purpose of the Study:

  • To evaluate the sensitization potential of the ICRC vaccine using Rees' MLSA and lepromin.
  • To assess the reactogenicity of the ICRC vaccine in the local population.
  • To determine the safety and immune response to the ICRC vaccine.

Main Methods:

  • A randomized controlled trial involving 368 healthy individuals aged 1-70 years.
  • Participants received either the ICRC vaccine or normal saline (control).
  • Sensitization was measured using Rees' MLSA and lepromin-A at 12 weeks post-vaccination; local reactions were monitored.

Related Experiment Videos

Main Results:

  • The ICRC vaccine demonstrated uneventful healing of vaccination lesions (mean size 10.3 mm).
  • Significantly higher post-vaccination reactions to Rees' MLSA and lepromin were observed in the vaccine group compared to the control group.
  • The vaccine induced a notable sensitizing effect, with mean reaction sizes of 3.5 mm (MLSA), 1.7 mm (early lepromin), and 2.2 mm (late lepromin).

Conclusions:

  • The ICRC vaccine is safe for use in the studied population.
  • The vaccine elicits a significant sensitizing effect, as indicated by immune responses to Rees' MLSA and lepromin.
  • These findings support the potential of the ICRC vaccine in anti-leprosy strategies.